Conception
Pablo Hurtado González has a diverse work experience in the field of reproductive health and embryology. Pablo is currently serving as the Co-Founder and CSO at Conception since 2018. Prior to this role, they worked as a Postdoctoral Fellow at the University of California, Los Angeles from January 2018 to July 2018, where they studied the correlation between environmental factor exposure during pregnancy and modifications of the epigenome in primordial germ cells. Pablo also focused on reconstituting mouse oogenesis in a dish from pluripotent stem cells.
Before that, Pablo completed their Reproductive Health PhD at The University of Edinburgh from October 2014 to September 2017. Pablo'sresearch during their PhD focused on the consequences of fetal exposure to analgesics for germ cells. Pablo discovered that exposure to common painkillers can reduce the proliferation rate of fetal germ cells and elucidated the mechanism of these effects.
In 2014, Pablo worked as an MSc Student at the Royal Veterinary College, where they studied the role of activin in human fetal ovarian somatic cells. Pablo also gained experience as an Undergraduate Assistant at the University of Cambridge in 2013 and at CBMSO-CNB in 2012.
Overall, Pablo Hurtado González has a strong background in reproductive health research, particularly in the study of fetal development and the effects of environmental factors on germ cells.
Pablo Hurtado González obtained a Licenciatura in Biochemistry from the Universidad Autónoma de Madrid from 2008 to 2013. Pablo then pursued a degree in Reproductive Science and Woman's Health at UCL from 2013 to 2014. Subsequently, they attended The University of Edinburgh where they completed their PhD in Reproductive Health from 2014 to 2017.
This person is not in any offices
Conception
Conception is a company developing the technology to turn skin cells into viable human eggs.This technology will give women the opportunity to have children well into their forties and fifties, eliminate barriers for couples suffering from infertility, and potentially allow male-male couples to have biological children.Long term, thistechnology could be a critical platform allowing for widespread genetic screening of embryos. If proven safe, it could even enable for genetic editing to eliminate and reduce the risk of devastating diseases for future generations – such as Alzheimer’s, heart disease and many different types of cancers.This could become one of the most important technologies ever created.The company was founded in 2018 and is headquartered in Berkeley, California.